Larimar Therapeutics
LRMR
62 hedge funds and large institutions have $47M invested in Larimar Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 12 closing their positions.
571% more call options, than puts
Call options by funds: $47K | Put options by funds: $7K
0% more capital invested
Capital invested by funds: $46.8M → $47M (+$194K)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
0.01% less ownership
Funds ownership: 4.06% → 4.05% (-0.01%)
10% less funds holding
Funds holding: 69 → 62 (-7)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.94M |
| 2 |
AC
Armistice Capital
New York
|
+$1.32M |
| 3 |
Renaissance Technologies
New York
|
+$886K |
| 4 |
6CM
683 Capital Management
New York
|
+$352K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$822K |
| 2 |
Goldman Sachs
New York
|
-$642K |
| 3 |
Millennium Management
New York
|
-$552K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$510K |
| 5 |
ECM
Element Capital Management
New York
|
-$316K |
LRMR Hedge Fund Activity: Q3 2017 in Review
62 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2017, worth a combined $47M — up 0.41% from $46.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LRMR and 6 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $1.94M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $822K sold.
- 62 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2017, down from 69 in Q2 2017.
- Funds reported $47M of Larimar Therapeutics stock for Q3 2017, up 0.41% quarter-over-quarter.
- 6 funds opened new Larimar Therapeutics positions in Q3 2017 and 12 closed out, a net change of -6 holders.
- The largest Larimar Therapeutics buyer in Q3 2017 was Mangrove Partners, an estimated $1.94M added.
- The largest Larimar Therapeutics seller in Q3 2017 was Foresite Capital Management III, an estimated $822K sold.
Based on aggregated 13F filings for Q3 2017.